CapsoVision, Inc. (CV)
CapsoVision will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
CapsoVision is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal tract for diagnostic and screening purposes.
We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-use capsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.
The CapsoCam Plus is classified as a Class II device and has received FDA marketing authorization through the 510(k) clearance process.
CapsoVision, Inc.
| Country | United States |
| Founded | 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 90 |
| CEO | Kang-Huai (Johnny) Wang |
Contact Details
Address: 18805 Cox Avenue, Suite 250 Saratoga, CA 95070 United States | |
| Phone | +1-408-624-1488 |
| Website | capsovision.com |
Stock Details
| Ticker Symbol | CV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001378325 |
| Employer ID | 20-3369494 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Kang-Huai (Johnny) Wang | President, Chief Executive Officer and Director |
| Kevin Lundquist | Chief Financial Officer |
| Rebecca Petersen | Director of Clinical Affairs |
| Douglas Atkinson | Head of Global Sales |
| Chen Lung Tsai | Chair |
| Hui Ying (Patty) Kuo | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 14, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 7, 2025 | DRS | [Cover] Draft Registration Statement |
| Jul 23, 2024 | D/A | Filing |
| Oct 19, 2023 | D/A | Filing |
| Mar 7, 2023 | D/A | Filing |
| Mar 11, 2021 | D/A | Filing |
| Jun 17, 2020 | D | Notice of Exempt Offering of Securities |
| Nov 26, 2019 | D | Notice of Exempt Offering of Securities |
| Oct 31, 2018 | D | Notice of Exempt Offering of Securities |